Watch Out Sanofi! Chinese Fast-Follower Emerges With Dupixent Rival
Promising Top-Line Data
Keymed’s anti-IL-4Rα antibody stapokibart has delivered compelling top-line efficacy and safety results in a China Phase III study, which could help it challenge Sanofi/Regeneron’s Dupixent in the country.
